Aaron Ring, Simcha Therapeutics founder
Going after an old GSK target in a new way, a Yale spinout hits the clinic and nabs a modest raise
About a year and a half ago, a Yale professor took a shot at engineering a cancer therapy that had once flummoxed researchers at GlaxoSmithKline …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
